OncoDaily IO/LinkedIn
Jul 30, 2025, 09:27
Top Immunotherapy Trials from ESMO GI 2025 – OncoDaily IO
OncoDaily IO shared a post on LinkedIn:
“Top Immunotherapy Trials – ESMO GI 2025 Highlights.
1. MATTERHORN (Phase III): Durvalumab + FLOT in resectable gastric/GEJ cancer
- 29% EFS risk reduction (HR 0.71, p<0.001)
- FDA Priority Review granted
2. SIERRA (Phase 3b): Durvalumab + Tremelimumab (STRIDE) in advanced HCC with poor-risk features
- Safe and feasible in CP B7/B8, ECOG 2, Vp4 patients
3. EXPEL PANC (Phase II): BXCL701 + Pembrolizumab in 2L pancreatic cancer
- DCR: 39%, PR: 17% – early signals in an immune-cold tumor
4, ABSK-011-201 (Phase II): Irpagratinib + Atezolizumab in FGF19+ HCC
- ORR >50%, mPFS ≥7mo – encouraging in biomarker-driven population
5, Givastomig Trial (Phase I/II): CLDN18.2/4-1BB bispecific + Nivo + FOLFOX in mGEC
- ORR 71%, effective even in low PD-L1/CLDN18.2 settings
These trials reflect real innovation – targeted, biomarker-driven, and inclusive of hard-to-treat GI cancers.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 30, 2025, 14:59
Jul 30, 2025, 14:51
Jul 30, 2025, 13:43
Jul 30, 2025, 13:30
Jul 30, 2025, 12:52
Jul 30, 2025, 11:57
Jul 30, 2025, 10:36